New Studies Validate the Value of Brainomix AI Technology Across US Stroke Networks

• The studies presented this week at the Society of Neurointerventional Surgery (SNIS) underline the company's rigorous evidence-based approach to developing and validating novel AI solutions that can help to optimize patient care across stroke networks.

OXFORD, England and CHICAGO, July 25, 2024 /PRNewswire/ -- Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, announced new data from studies that were presented this week at the US-based Society of Neurointerventional Surgery's (SNIS) Annual Meeting in Colorado Springs. The latest research, in collaboration with the Mayo Clinic, West Virginia University, and Boston Medical Center, highlighted some of the cutting-edge, AI-enabled technology that the Oxford-based company has developed within its pipeline for the Brainomix 360 Stroke platform, representing groundbreaking capabilities that will enable physicians to extract maximal value from universally available non-contrast CT scans across stroke networks.

The FDA-cleared Brainomix 360 Stroke platform is powered by state-of-the-art AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients, with the aim of enabling more patients to receive the right treatment, in the right place, at the right time.

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: "The studies presented this week at SNIS symbolize our ongoing commitment to scientific excellence and reflect the successful partnerships that we have forged with leading academic institutions across the United States to jointly explore the frontiers of stroke AI imaging. Together we are identifying exciting opportunities that may expand the capabilities of physicians to better manage stroke patients across all levels of stroke networks with our technology."

Dr Ansaar Rai, Professor and Chair, Department of Neuroradiology & Neurointerventional Surgery, West Virginia University, said: "The studies presented this week at SNIS highlight the clinical value of the Brainomix 360 Stroke platform, particularly relating to the e-ASPECTS and Triage Stroke algorithms that assess non-contrast CT scans, which are universally available to all stroke centers across the US. The results indicate that these algorithms generate clinically relevant results for frontline stroke physicians that could help them to better manage stroke patients eligible for mechanical thrombectomy across all centers within a network."

Key studies presented at SNIS included:

• "AI Derived Clot Characteristics Predict Recanalization Success in Large Vessel Acute Stroke Patients Undergoing Mechanical Thrombectomy" was a research collaboration between Brainomix and West Virginia University in which baseline non-contrast CT (NCCT) scans from patients with large vessel occlusion (LVO) were analyzed with Brainomix 360 e-ASPECTS to identify hyperdense clots and quantify their length. The results showed that clot biomarkers from NCCT are predictors of successful recanalization and could facilitate the planning of mechanical thrombectomy (MT) procedures.
• "Large Vessel Occlusion Detection in Acute Ischemic Stroke Using Non-Contrast CT" was a multisite collaboration with the Mayo Clinic, West Virginia University, and Boston Medical Center validating Triage Stroke as a reliable tool for LVO detection. The authors concluded that when coupled with clinical information such as NIHSS, the tool may help centers to identify thrombectomy candidates, especially those with constrained resources and basic imaging.
• "How Dark Is Too Dark? Using Net-Water Uptake to Predict Futile Recanalization Following Mechanical Thrombectomy" was another multisite collaboration, this one between the Mayo Clinic, West Virginia University and Brainomix. Ischemic core volume and depth of hypoattenuation using Net Water Uptake (NWU) were quantified from baseline CT scans using Brainomix 360 e-ASPECTS, with results showing that NWU extracted automatically from routine imaging may help identify patients at risk of futile recanalization – especially those with large cores.

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730

Media enquiries

Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585

Logo: https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg

SOURCE Brainomix